Floatz Rating
B57/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05656248CT.gov Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT04526288CT.gov CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease | — | Terminated | — | — | — |
NCT04195945CT.gov CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cpx-351 (this asset) | St. Jude Children's Research Hospital | P2 | B · 57 |
| Cytarabine | First Affiliated Hospital of Zhejiang University | P3 | BBB |
| Mitoxantrone | First Affiliated Hospital of Zhejiang University | P3 | BBB |
| Cladribine | University of Washington | P2 | BBB |
| Cyclophosphamide | Prelude Therapeutics | P3 | BB |
| Idarubicin | Northwestern University | P3 | BB |
| Venetoclax | First Affiliated Hospital of Zhejiang University | P3 | BB |
| Recombinant Human Granulocyte Colony-Stimulating Factor | University of Washington | P2 | BB |
| Fludarabine | First Affiliated Hospital of Zhejiang University | P3 | BB |
+38 more in the Myeloid Neoplasm cohort
Other indications for Cpx-351
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome | — | P2 | BB · 67 |
| Myelodysplastic Syndrome | — | P2/3 | B · 63 |
| Acute Myeloid Leukemia | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cpx-351 in Myeloid Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cpx-351-myeloid-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →